Venn-Watson, Stephanie
Lumpkin, Richard
Dennis, Edward A.
Article History
Received: 21 January 2020
Accepted: 20 April 2020
First Online: 18 May 2020
Competing interests
: S.V. is a co-founder of and employed by Epitracker, Inc and Seraphina Therapeutics, Inc, which financed studies in this paper and hold exclusive licensing rights from the U.S. Navy to commercialize odd-chain saturated fatty acids as human and animal health products. R. Lumpkinās work related to this study was also financed by Epitracker. E.A. Dennis is a member of the Scientific Advisory Board of Epitracker and holds equity.